TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06169618

Intervention type: OTHER
Intervention: cervical radiculopathy
Description: this group will have patients with cervical radiculopathy

Intervention type: OTHER
Intervention: normal group
Description: this group will have normal subjects
Study: NCT06197737

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacological treatment
Description: They will be on pharmacological treatment as prescribed by their pulmonologist.
Study: NCT04976998

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: imaging by ultrasonography and nerve conduction studies will be done for both grups

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: imaging by ultrasonography and nerve conduction studies will be done for both grups
Study: NCT05354570

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Pleural Radiation Therapy (IMPRINT)
Description: Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.
Study: NCT05551455

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional/dietary intake manipulation ('Normal')
Description: Energy Intake provision (60 kcal/kg FFM/day) to elicit 'normal' energy availability (45 kcal/kg FFM/day), with 60% from carbohydrates.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional/dietary intake manipulation ('Low')
Description: Energy Intake provision (60 kcal/kg FFM/day), with 1.5 g/kg of carbohydrate and 70-80% fat intake, to elicit 'low' carbohydrate availability in energy balance (45 kcal/kg FFM/day).
Study: NCT05358457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familiar Metacognitive Training
Description: The original metacognitive training program consist of 8 therapeutic units and 2 complementary. Seven of the therapeutic units address cognitive deviations and errors that are frequently seen in problem solving in schizophrenia, involved in the formation and maintenance of delusions. The other three units work with metacognition and the aims of the progra, as a psychoeducation session, so in total the MCTf will include 11 sessions.
Study: NCT05733507

Intervention type: PROCEDURE
Intervention: IVT with tenecteplase or alteplase
Description: Patients received intravenous tenecteplase 0.25mg/kg (maximum dose: 25mg), administered as a bolus over 5 to 10 seconds or intravenous alteplase 0.9 mg/kg (maximum dose: 90mg), 10% as bolus and the remainder as continuous perfusion over 1 hour.

Intervention type: PROCEDURE
Intervention: Intervention Name : Tirofiban and IVT with tenecteplase or alteplase
Description: IVT with tenecteplase or alteplase with continuous infusion of tirofiban 0.4µg/kg/min continued for 24 to 48 hours.
Study: NCT05494294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraorally de-epithelialization
Description: In this group, the grafts were de-epithelialized at the donor site before harvesting. The calibrated surgeon removed the epithelium with a sharp Kirkland knife under magnification. To be sure of the elimination whole epithelial layer, bleeding was observed. Recipient site was prepared as follows; A after sulculer incision had done (blade 15c) two vertical incions were made from the gingival margin to 3 mm beyond the mucogingival junction A partial-thickness flap was elevated under the recession area and full thickness flap elevated adjacent flap portions. then relasing incisions were made apically from the mucogingival junction. After the preparation of the recipient site, obtained graft was sutured 1 mm apically to the cemento-enamel junction. Finally flap was positioned without tension and stabilized at least 2mm coronally from the cemento-enamel margin with the single interrupted sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraorally de-epithelialization
Description: In this group, the grafts were de-epithelialized after graft harvesting. The calibrated surgeon removed the epithelium with 15 c knife under magnification. all remnants were removed under magnification. Same recipient site procedure was conducted in this group.
Study: NCT05519670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Oral Product
Description: Niraparib + capecitabine treatment
Study: NCT05877807

Intervention type: DRUG
Intervention: Baclofen
Description: Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.

Intervention type: OTHER
Intervention: Placebo
Description: Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
Study: NCT05466656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous quality improvement cycle model
Description: The continuous quality improvement cycle model consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying barriers to improvements in clinical practice, and drawing up and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
Study: NCT05901571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham-acupuncure
Description: In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham-acupuncure
Description: In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.
Study: NCT06451016

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplements
Description: 70 mcg/day (equal to 2800 IU) of cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT05901571

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram placebo
Description: Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: escitalopram placebo
Description: Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.
Study: NCT05680935

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood microRNA
Description: all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood microRNA
Description: all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: plaque and intima microRNA
Description: The resulting surgical material will be sent for microRNA isolation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: histological examination of the plaque
Description: The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood level trimethyl N-oxide
Description: all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood level trimethyl N-oxide
Description: all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.
Study: NCT05914935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant L-IFN adenovirus injection
Description: The Ommaya reservoir was surgically implanted, and multiple intracapsular injections were given medicine. On the second day after Ommaya reservoir implantation, CT examination confirmed that the implantation was successful, and the experimental drug injection was started.
Study: NCT06505876

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment
Description: including anti-infection therapy, blood pressure and blood glucose control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: including anti-infection therapy, blood pressure and blood glucose control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral Tube Feeding
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study: NCT06295406

Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: Neuropsychological tests assessing reading abilities, skills of motor coordination, postural stability, manual dexterity, including graphomotor skills, and estimation of time will be performed
Study: NCT06064903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7-CART01
Description: A single IV infusion of CD7-CART01 on Day 0
Study: NCT05628519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Captain Sonar Exposition
Description: Captain SonarTM is a naval battle game where two teams each composed of four participants clash. Each player has a well-defined role and it is imperative to communicate in a closed loop to advance in the game. This game also includes components similar to support for Trauma care: stress, speed of action, central communication and teamwork of four protagonists (Team Leader- Captain, intern-Second, nurse-Mechanic, Caregiver-Detector). This short video describes the rules and the Game progress: https://vimeo.com/173614346.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Monopoly Exposition
Description: Participant will be invited to play to Monopoly during 60 min
Study: NCT04670666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MADALENA ASSOCIATION
Description: Madalena association coated tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METFORMIN
Description: Metformin 1000 mg extended-release tablet.
Study: NCT05934383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paradise® ultrasound renal denervation system.
Description: Bilateral renal sympathetic denervation of the native kidneys using the Paradise® ultrasound renal denervation system.
Study: NCT04983771

Intervention type: DEVICE
Intervention: Annotate ultrasound scans
Description: Each expert will be asked to hand-labelled anatomical structures on relevant ultrasound images
Study: NCT06231407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Oriented CBTp Medication Management
Description: The prescriber structures the medication appointment to elicit and focus on subjects long term, valued goals (aspirations). With this information the prescriber will develop a plan to increase daily activity to facilitate the aspiration's pursuit. Obstacles (psychotic symptoms, motivational problems) will be identified and a formulation developed with the individual. Psychosocial interventions will be implemented for the various obstacles alongside monitoring and implementing of medications. Across sessions, the prescriber will continue to implement and monitor psychosocial interventions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Residents will conduct medication management appointments as normally conducted
Study: NCT05524636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise with peripheral magnetic stimulation of the abdominal wall muscles
Description: 8-week exercise program with peripheral magnetic stimulation, focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
Study: NCT04670666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMPAGLIFLOZIN + LINAGLIPTIN
Description: Empagliflozin 10 mg + linagliptin 5 mg coated tablet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MADALENA ASSOCIATION PLACEBO
Description: Madalena association placebo tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: METFORMIN PLACEBO
Description: Metformin placebo tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO
Description: Empagliflozin + linagliptin placebo tablet.
Study: NCT05524636

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise of the abdominal wall muscles
Description: 8-week exercise program focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
Study: NCT06181695

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: Administration of intranasal sufentanil
Study: NCT04952636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic Cuistow
Description: peforming the Cuistow Procedure under arthroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open Cuistow
Description: peforming the Cuistow Procedure with the traditional open process
Study: NCT05179798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile app
Description: Lifestyle modification, insulin therapy if needed, utilization of a mobile app with personalized recommendations.
Study: NCT05795075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computerized Modified Paramedian Approach Technique
Description: Computerized Modified Paramedian Approach Technique ( CMPAT )
Study: NCT06181695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Administration of intranasal sufentanil
Study: NCT05160506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone is a steroid (corticosteroid) medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50ml of 0.9% NACL will serve as the placebo
Study: NCT05407805

Intervention type: OTHER
Intervention: Electronic Diary
Description: Participants will be asked to complete a daily electronic patient reported outcome diary entry to report on their experience in the past 24 hours.

Intervention type: OTHER
Intervention: Electronic Diary
Description: Participants will be asked to complete a daily electronic patient reported outcome diary entry to report on their experience in the past 24 hours.
Study: NCT06221436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery
Description: Olfactory mental imagery is the ability to detect an odor in the absence of any odor stimulus.~Participants will be asked to choose their 4 favorite fragrances from 20 different scents (such as rose, lavender scent) determined by the researcher and proven to have positive effects on mind-body therapy. The determined odors will be visualized by the researcher and picture cards measuring 15X12 cm (for example, a card with a rose picture for the rose smell, etc.) will be created. Participants will visualize the smell by looking at the picture cards, so they will be expected to make their breathing exercises more effective. Vagus breathing technique will be combined with olfactory mental imagery.
Study: NCT05733637

Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention apply to study participants.
Study: NCT05795075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Midline Approach Technique
Description: Conventional Midline Approach Technique
Study: NCT06136351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up
Study: NCT06515015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial Silicon Spigots
Description: The single-use endobronchial silicon spigot is injection-molded from implant-grade silicone and has a solid conical body. The endobronchial silicon spigot is used for the temporary occlusion of the target bronchus. It is delivered to the target bronchus through a bronchoscope using biopsy forceps, and the position of the blocker is adjusted to occlude the responsible bronchus leading to the pleural air leakage.
Study: NCT06312163

Intervention type: DEVICE
Intervention: The contact lens to be investigated in this study (Scheimpflug topography derived corneal RGP contact lens design). A CE (UKCA) marked class 2 medical devices.
Description: The participants will be fitted with (i) the optimal lens design as specified by the virtual fitting module, in addition to (ii) lenses that are one clinically significant step (0.12 mm) flatter and (iii) steeper in axial edge lift (AEL).

Intervention type: DEVICE
Intervention: The contact lens to be investigated in this study (Scheimpflug topography derived corneal RGP contact lens design). A CE (UKCA) marked class 2 medical devices.
Description: The participants will be fitted with (i) the optimal lens design as specified by the virtual fitting module, in addition to (ii) lenses that are one clinically significant step (0.12 mm) flatter and (iii) steeper in axial edge lift (AEL).
Study: NCT05502003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Telerehabilitation-based high-intensity exercise training will be applied to the participants for 6 weeks, 3 times a week for 35 minutes, under the control of a physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Exercise Training
Description: The participants will be given telerehabilitation-based moderate exercise training under the control of a physiotherapist for 55 minutes, 3 times a week for 6 weeks.
Study: NCT06070818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Body & Mind Program
Description: 12-week physical activity and lifestyle education program
Study: NCT06032858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30mg twice daily